- Home
- MDLZ vs BMY Comparison
MDLZ vs BMY Comparison
Compare MDLZ & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDLZ
- BMY
- Stock Information
- Founded
- MDLZ 2000
- BMY 1887
- Country
- MDLZ United States
- BMY United States
- Employees
- MDLZ N/A
- BMY N/A
- Industry
- MDLZ Packaged Foods
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- MDLZ Consumer Staples
- BMY Health Care
- Exchange
- MDLZ Nasdaq
- BMY Nasdaq
- Market Cap
- MDLZ 88.4B
- BMY 97.6B
- IPO Year
- MDLZ N/A
- BMY N/A
- Fundamental
- Price
- MDLZ $67.26
- BMY $46.50
- Analyst Decision
- MDLZ Buy
- BMY Hold
- Analyst Count
- MDLZ 18
- BMY 16
- Target Price
- MDLZ $70.89
- BMY $58.33
- AVG Volume (30 Days)
- MDLZ 6.3M
- BMY 13.5M
- Earning Date
- MDLZ 07-29-2025
- BMY 07-31-2025
- Dividend Yield
- MDLZ 2.79%
- BMY 5.35%
- EPS Growth
- MDLZ N/A
- BMY N/A
- EPS
- MDLZ 2.70
- BMY 2.67
- Revenue
- MDLZ $36,464,000,000.00
- BMY $47,636,000,000.00
- Revenue This Year
- MDLZ $7.21
- BMY N/A
- Revenue Next Year
- MDLZ $4.24
- BMY N/A
- P/E Ratio
- MDLZ $25.00
- BMY $17.36
- Revenue Growth
- MDLZ 0.90
- BMY 4.62
- 52 Week Low
- MDLZ $53.95
- BMY $39.35
- 52 Week High
- MDLZ $76.06
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- MDLZ 54.48
- BMY 39.67
- Support Level
- MDLZ $67.12
- BMY $46.18
- Resistance Level
- MDLZ $68.80
- BMY $47.07
- Average True Range (ATR)
- MDLZ 1.12
- BMY 0.85
- MACD
- MDLZ 0.05
- BMY -0.18
- Stochastic Oscillator
- MDLZ 67.52
- BMY 7.18
About MDLZ Mondelez International Inc.
Mondelez has operated independently since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (49% of sales), chocolate (31%), gum/candy (11%), beverage (3%), and cheese and grocery (6%) aisles, as of the end of fiscal 2024. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury. The firm derives around one third of its revenue from developing markets, just more than one third from Europe, and the remainder from North America.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.